Page last updated: 2024-10-16

carbamates and Akinetic-Rigid Variant of Huntington Disease

carbamates has been researched along with Akinetic-Rigid Variant of Huntington Disease in 3 studies

Research Excerpts

ExcerptRelevanceReference
" In the R6/2 mouse HD model, induced DREAM haplodeficiency or blockade of DREAM activity by chronic administration of the drug repaglinide delayed onset of motor dysfunction, reduced striatal atrophy, and prolonged life span."1.43Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease. ( Arrabal, MD; Casado-Vela, J; Cercós, P; De la Cruz, A; Dopazo, XM; González, P; González, T; Gutierrez-Rodriguez, M; Higueras, E; Li, JY; Mellström, B; Morón-Oset, J; Naranjo, JR; Oliveros, JC; Prieto, A; Rábano, A; Valenzuela, C; Villar, D; Zhang, H, 2016)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
López-Hurtado, A1
Burgos, DF1
González, P2
Dopazo, XM2
González, V1
Rábano, A2
Mellström, B2
Naranjo, JR2
Zhang, H1
Villar, D1
Morón-Oset, J1
Higueras, E1
Oliveros, JC1
Arrabal, MD1
Prieto, A1
Cercós, P1
González, T1
De la Cruz, A1
Casado-Vela, J1
Valenzuela, C1
Gutierrez-Rodriguez, M1
Li, JY1
Rot, U1
Kobal, J1
Sever, A1
Pirtosek, Z1
Mesec, A1

Other Studies

3 other studies available for carbamates and Akinetic-Rigid Variant of Huntington Disease

ArticleYear
Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.
    Molecular brain, 2018, 03-09, Volume: 11, Issue:1

    Topics: Activating Transcription Factor 6; Animals; Carbamates; Cognition Disorders; Disease Models, Animal;

2018
Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease.
    The Journal of clinical investigation, 2016, Volume: 126, Issue:2

    Topics: Activating Transcription Factor 6; Animals; Carbamates; CHO Cells; Corpus Striatum; Cricetulus; Dise

2016
Rivastigmine in the treatment of Huntington's disease.
    European journal of neurology, 2002, Volume: 9, Issue:6

    Topics: Carbamates; Cholinesterase Inhibitors; Humans; Huntington Disease; Phenylcarbamates; Rivastigmine

2002